Does the media refer more to COYA or MCRB?

In the previous week, Coya Therapeutics had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Coya Therapeutics and 2 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.60 beat Coya Therapeutics' score of 0.56 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MCRB or RANI?

In the previous week, Seres Therapeutics and Seres Therapeutics both had 2 articles in the media. Rani Therapeutics' average media sentiment score of 1.35 beat Seres Therapeutics' score of 0.60 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FHTX or MCRB?

In the previous week, Foghorn Therapeutics had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for Foghorn Therapeutics and 2 mentions for Seres Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.75 beat Seres Therapeutics' score of 0.60 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MCRB or BDTX?

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Seres Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.12 beat Seres Therapeutics' score of 0.60 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Seres Therapeutics (MCRB) Competitors

$2.42 -0.11 (-4.35%)

Closing price 04:00 PM Eastern

Extended Trading

$2.52 +0.10 (+3.93%)

As of 04:55 PM Eastern

Compare

MCRB vs. COYA, RANI, FHTX, BDTX, and CRBP

Should you buy Seres Therapeutics stock or one of its competitors? Seres Therapeutics's main competitors and comparable companies include Coya Therapeutics (COYA), Rani Therapeutics (RANI), Foghorn Therapeutics (FHTX), Black Diamond Therapeutics (BDTX), and Corbus Pharmaceuticals (CRBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Seres Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, Coya Therapeutics had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Coya Therapeutics and 2 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.60 beat Coya Therapeutics' score of 0.56 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Coya Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 243.03%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 571.94%. Given Seres Therapeutics' higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Coya Therapeutics has a net margin of -270.22% compared to Seres Therapeutics' net margin of -1,192.94%. Coya Therapeutics' return on equity of -52.05% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Seres Therapeutics has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.19	-$21.23M	-$1.07	N/A
Seres Therapeutics	$790K	32.19	$5.70M	-$2.43	N/A

Summary

Coya Therapeutics beats Seres Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Rani Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Seres Therapeutics has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	32.19	$5.70M	-$2.43	N/A
Rani Therapeutics	$1.63M	62.70	-$29.67M	-$0.27	N/A

Rani Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Rani Therapeutics' return on equity of -104.60% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Rani Therapeutics	N/A	-104.60%	-65.17%

Seres Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Seres Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 571.94%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 1,093.40%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Seres Therapeutics and Seres Therapeutics both had 2 articles in the media. Rani Therapeutics' average media sentiment score of 1.35 beat Seres Therapeutics' score of 0.60 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rani Therapeutics beats Seres Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Foghorn Therapeutics has a net margin of -175.78% compared to Seres Therapeutics' net margin of -1,192.94%. Foghorn Therapeutics' return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Seres Therapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	3.55	-$74.28M	-$0.98	N/A
Seres Therapeutics	$790K	32.19	$5.70M	-$2.43	N/A

In the previous week, Foghorn Therapeutics had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for Foghorn Therapeutics and 2 mentions for Seres Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.75 beat Seres Therapeutics' score of 0.60 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Foghorn Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Foghorn Therapeutics presently has a consensus target price of $6.14, indicating a potential upside of 232.05%. Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 571.94%. Given Seres Therapeutics' higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Foghorn Therapeutics beats Seres Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Black Diamond Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Black Diamond Therapeutics has higher revenue and earnings than Seres Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	32.19	$5.70M	-$2.43	N/A
Black Diamond Therapeutics	$70M	1.38	$22.37M	-$0.75	N/A

Black Diamond Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Black Diamond Therapeutics' return on equity of -32.10% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Seres Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.32, suggesting that its share price is 232% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Seres Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.12 beat Seres Therapeutics' score of 0.60 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 571.94%. Black Diamond Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 510.12%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Black Diamond Therapeutics beats Seres Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Corbus Pharmaceuticals presently has a consensus price target of $41.00, indicating a potential upside of 757.74%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 571.94%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corbus Pharmaceuticals is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Seres Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
Seres Therapeutics	$790K	32.19	$5.70M	-$2.43	N/A

Corbus Pharmaceuticals has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Corbus Pharmaceuticals' return on equity of -87.05% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

In the previous week, Seres Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 2 mentions for Seres Therapeutics and 1 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.82 beat Seres Therapeutics' score of 0.60 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Very Positive
Seres Therapeutics	Positive

Corbus Pharmaceuticals has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Summary

Corbus Pharmaceuticals beats Seres Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.31M	$3.90B	$7.28B	$12.92B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-1.00	12.63	275.31	25.29
Price / Sales	12.91	1,151.58	556.96	76.42
Price / Cash	2.47	118.50	77.16	53.04
Price / Book	0.49	16.54	10.51	5.92
Net Income	$5.70M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-11.03%	-6.63%	-4.32%	-4.38%
1 Month Performance	-48.84%	-14.38%	-8.66%	-7.26%
1 Year Performance	-87.72%	6.02%	2.01%	-4.96%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	2.5276 of 5 stars	$2.42 -4.3%	$17.00 +602.5%	-86.8%	$24.31M	$1.88M	N/A	66	Gap Up
COYA Coya Therapeutics	2.3067 of 5 stars	$4.82 -0.7%	$15.33 +218.4%	-26.2%	$111.93M	$7.95M	N/A	8	News Coverage Gap Up
RANI Rani Therapeutics	2.7749 of 5 stars	$0.80 +3.2%	$8.75 +993.8%	+56.5%	$111.52M	$1.63M	N/A	69	News Coverage Gap Down
FHTX Foghorn Therapeutics	2.22 of 5 stars	$1.85 -7.8%	$6.67 +261.3%	-56.9%	$109.57M	$36.74M	N/A	106	Analyst Downgrade
BDTX Black Diamond Therapeutics	3.6921 of 5 stars	$1.88 -3.4%	$10.25 +446.7%	-55.8%	$107.73M	N/A	N/A	21	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. COYA, RANI, FHTX, BDTX, and CRBP

How does Seres Therapeutics compare to Coya Therapeutics?

Summary

How does Seres Therapeutics compare to Rani Therapeutics?

Summary

How does Seres Therapeutics compare to Foghorn Therapeutics?

Summary

How does Seres Therapeutics compare to Black Diamond Therapeutics?

Summary

How does Seres Therapeutics compare to Corbus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. COYA, RANI, FHTX, BDTX, and CRBP

How does Seres Therapeutics compare to Coya Therapeutics?

Does the media refer more to COYA or MCRB?

Which has more volatility and risk, COYA or MCRB?

Do insiders and institutionals believe in COYA or MCRB?

Do analysts prefer COYA or MCRB?

Is COYA or MCRB more profitable?

Which has better earnings & valuation, COYA or MCRB?

Summary

How does Seres Therapeutics compare to Rani Therapeutics?

Which has better valuation and earnings, MCRB or RANI?

Is MCRB or RANI more profitable?

Which has more volatility & risk, MCRB or RANI?

Do analysts recommend MCRB or RANI?

Do institutionals and insiders hold more shares of MCRB or RANI?

Does the media favor MCRB or RANI?

Summary

How does Seres Therapeutics compare to Foghorn Therapeutics?

Do institutionals & insiders believe in FHTX or MCRB?

Is FHTX or MCRB more profitable?

Which has stronger valuation & earnings, FHTX or MCRB?

Does the media refer more to FHTX or MCRB?

Which has more risk and volatility, FHTX or MCRB?

Do analysts recommend FHTX or MCRB?

Summary

How does Seres Therapeutics compare to Black Diamond Therapeutics?

Which has higher valuation and earnings, MCRB or BDTX?

Is MCRB or BDTX more profitable?

Do institutionals and insiders hold more shares of MCRB or BDTX?

Which has more volatility & risk, MCRB or BDTX?

Does the media prefer MCRB or BDTX?

Do analysts prefer MCRB or BDTX?

Summary

How does Seres Therapeutics compare to Corbus Pharmaceuticals?

Do analysts rate CRBP or MCRB?

Do insiders and institutionals believe in CRBP or MCRB?

Which has better valuation & earnings, CRBP or MCRB?

Is CRBP or MCRB more profitable?

Does the media refer more to CRBP or MCRB?

Which has more risk and volatility, CRBP or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools